Skip to main content
. 2024 Feb 12;13(4):995–1014. doi: 10.1007/s40123-024-00898-y

Fig. 3.

Fig. 3

The proportion of patients who did not require additional topical glaucoma medications was similar in the SE-implant group and in the FE-implant group compared to the timolol group at each visit (P > 0.05, Fisher’s exact test). FE-implant fast-eluting travoprost intracameral implant, SE-implant slow-eluting travoprost intracameral implant